Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Type 2 Diabetes (FORTUNA)
NCT01140542Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Roflumilast with Placebo (2 arms). Primary endpoint: Glycated Hemoglobin at 12 weeks. Started Aug 2006; status: completed.
02
Drugs
roflumilast
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01140542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01140542.